OR WAIT null SECS
© 2021 MJH Life Sciences and Endocrinology Network. All rights reserved.
© 2021 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
June 28, 2021
June 27, 2021
Coverage of the American Diabetes Association's 81st Scientific Sessions (ADA 2021)
A simulation model assesses the projected impact of the Medicare Part D Senior Savings Model on healthcare spending and outcomes among patients covered by Medicare using insulin.
A look at the medical spending of more than 500 patients with type 2 diabetes who initiated therapy with real-time continuous glucose monitoring details the reductions in medical costs associated with initiation of real-time CGM.
June 26, 2021
A study assessing use of remote patient monitoring in patients with type 2 diabetes outlines the impact continued participation in digital monitoring programs can have on glycemic control among this patient population.
A FIDELIO-DKD analysis presented at ADA 2021 suggests the renal and cardiovascular benefits of finerenone were consistent, irrespective of background GLP-1 RA use and indicate the presence of both was associated with even greater reductions in albuminuria.
A study assessing factors associated with achieving recommended levels of HbA1c testing provide insight into the impact of provider type and other factors on the likelihood of having at least 2 HbA1c measurements in a year.
While advances in glucose-lowering therapies have been practice-changing, a new analysis suggests patients could achieve greater cost-effectiveness with older agents.
June 25, 2021
A prespecified analysis of DAPA-CKD presented at ADA 2021 suggests use of dapagliflozin reduced the incidence of type 2 diabetes by nearly 40% among patients with chronic kidney disease but without diabetes within the phase 3 trial.
While investigators found no differences in outcomes based on diabetes status alone, results indicated those who were not managing their diabetes had more severe outcomes and longer length of hospitalization from COVID-19.
Data from an analysis of FIDELIO-DKD suggests the renoprotective benefits of finerenone were consistent irrespective of SGLT2 inhibitor use and those using an SGLT2 inhibitor with finerenone resulted in greater UACR reductions.
Ahead of ADA 2021, Dr. Thomas Wadden discusses the significance of the semaglutide 2.4 mg (Wegovy) approval for chronic weight management and Novo Nordisk's plans to evaluate an oral version.